Rational use of trastuzumab in metastatic and locally advanced breast cancer: Implications of recent research

Breast

Volumn 20, Issue 2, 2011, Pages 101-110

  Goel, Shom ^a   Chirgwin, Jacquie ^b   Francis, Prudence ^c   Stuart Harris, Robin ^d   Dewar, Joanna ^e   Mileshkin, Linda ^c   Snyder, Ray ^f   Michael, Michael ^c   Koczwara, Bogda ^g  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b Box Hill and Maroondah Hospitals ^*  (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d Capital Region Cancer Service   (Australia)

^e SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^f ST VINCENT S HOSPITAL   (Australia)

^g FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Breast cancer; Locally advanced; Metastatic; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; LAPATINIB; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; PERTUZUMAB; PLACEBO; PLATINUM COMPLEX; TAXANE DERIVATIVE; TRASTUZUMAB; VASCULOTROPIN INHIBITOR; VINCA ALKALOID;

ADVANCED CANCER; ALOPECIA; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RESEARCH; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG CHOICE; DRUG COST; DRUG CYTOTOXICITY; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; INFLAMMATORY BREAST CANCER; LOADING DRUG DOSE; MAINTENANCE THERAPY; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PARTIAL MASTECTOMY; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 79952631264     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.11.008     Document Type: Review

References (89)

1. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51.
2. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
3. Tovey S.M., Brown J., Doughty J.C., Mallon E., Cooke T.G., Edwards J. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer 2009, 100:680-683.
4. Rakkhit R., Broglio K., Peintinger F., Cardoso F., Hanrahan E.O., Gonzalez-Angulo A.M. Significant increased recurrence rates among breast cancer patients with HER2-positive. T1a, bN0M0 tumors (abstr). Cancer Res 2009, 69(Suppl). 701.
5. Chia S., Norris B., Speers C., Cheang M., Gilks B., Gown A.M., et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008, 26:5697-5704.
6. Dawood S., Broglio K., Buzdar A.U., Hortobagyi G.N., Giordano S.H. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010, 28:92-98.
7. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
8. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274.
9. Gasparini G., Gion M., Mariani L., Papaldo P., Crivellari D., Filippelli G., et al. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat 2007, 101:355-365.
10. Trastuzumab for HER2-positive breast cancer: a systematic review. Camperdown, NSW, Australia: National Breast Cancer Centre 2007.
11. Pegram M.D., Konecny G.E., O'Callaghan C., Beryt M., Pietras R., Slamon D.J. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004, 96:739-749.
12. Gianni L., Eiermann W., Semiglazov V., Manikhas A., Lluch A., Tjulandin S., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384.
13. Untch M., Muscholl M., Tjulandin S., Jonat W., Meerpohl H.G., Lichinitser M., et al. First-Line Trastuzumab Plus Epirubicin and Cyclophosphamide Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Cardiac Safety and Efficacy Data From the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) Trial. J Clin Oncol 2010, 28:1473-1490.
14. Rayson D., Richel D., Chia S., Jackisch C., van der Vegt S., Suter T. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol 2008, 19:1530-1539.
15. Andreopoulou E., Gaiotti D., Kim E., Volm M., Oratz R., Freedberg R., et al. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2007, 7:690-696.
16. Chia S., Clemons M., Martin L.A., Rodgers A., Gelmon K., Pond G.R., et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006, 24:2773-2778.
17. Seidman A., Conlin A.K., Bach A., Brufsky A., Saleh M., Lake D., et al. Phase II study of weekly nanoparticle albumin bound (nab)paclitaxel with carboplatin and trastuzuma as 1st-line therapy for HER2-positiv metastatic breast cancer (MBC). ASCO 2008 Annual Meeting 2008, Abstract 1047.
18. Mirtsching B., Cosgriff T., Harker G., Keaton M., Chidiac T., Min M. Single-agent nab-paclitaxel given weekly (3/4) as first-line therapy for metastatic breast cancer (an International Oncology Network study, #I-04-012). ASCO 2008 Annual Meeting 2008, Abstract 1118.
19. Chan A. A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. Ann Oncol 2007, 18:1152-1158.
20. Andersson M., Lidbrink E., Wist E., Enevoldsen K., Jensen A.B., Sorensen P.G., et al. Similar outcome in a randomized phase III trial comparing docetaxel versus vinorelbine both combined with trastuzumab as first line treatment for metastatic or locally advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer. European Journal of Cancer Supplements 2010, 8:55.
21. Pegram M., Hsu S., Lewis G., Pietras R., Beryt M., Sliwkowski M., et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999, 18:2241-2251.
22. Fujimoto-Ouchi K., Sekiguchi F., Tanaka Y. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models. Cancer Chemother Pharmacol 2002, 49:211-216.
23. Schaller G., Fuchs I., Gonsch T., Weber J., Kleine-Tebbe A., Klare P., et al. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 2007, 25:3246-3250.
24. Bartsch R., Wenzel C., Altorjai G., Pluschnig U., Rudas M., Mader R.M., et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007, 25:3853-3858.
25. Xu L., Song S., Zhu J., Luo R., Li L., Jiao S., et al. A phase II trial of trastuzumab (H) + capecitabine (X) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC). J Clin Oncol 2006, 24:10615.
26. von Minckwitz G., du Bois A., Schmidt M., Maass N., Cufer T., de Jongh F.E., et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009.
27. Bartsch R., Wenzel C., Gampenrieder S.P., Pluschnig U., Altorjai G., Rudas M., et al. Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. Cancer Chemother Pharmacol 2008, 62:903-910.
28. Brufsky A., Fox K., Orlando M., Abraham J., Tan-Chiu E., Haney L., et al. Phase II study of gemcitabine (Gem) and trastuzumab (T) combination therapy in first line metastatic breast cancer (MBC) patients (pts) with HER2 overexpression. J Clin Oncol 2006, 24:10591.
29. O'Shaughnessy J.A., Vukelja S., Marsland T., Kimmel G., Ratnam S., Pippen J.E. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 2004, 5:142-147.
30. Pietras R.J., Pegram M.D., Finn R.S., Maneval D.A., Slamon D.J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998, 17:2235-2249.
31. Pegram M.D., Lipton A., Hayes D.F., Weber B.L., Baselga J.M., Tripathy D., et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998, 16:2659-2671.
32. Pegram M.D., Pienkowski T., Northfelt D.W., Eiermann W., Patel R., Fumoleau P., et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004, 96:759-769.
33. Robert N., Leyland-Jones B., Asmar L., Belt R., Ilegbodu D., Loesch D., et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006, 24:2786-2792.
34. Pegram M., Forbes J., Pienkowski T., Valero V., Eiermann W., Von Minckwitz G., et al. BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol 2007, 25:1008.
35. Wardley A.M., Pivot X., Morales-Vasquez F., Zetina L.M., de Fatima Dias Gaui M., Reyes D.O., et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 2010, 28:976-983.
36. Fountzilas G., Christodoulou C., Tsavdaridis D., Kalogera-Fountzila A., Aravantinos G., Razis E., et al. Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Cancer Invest 2004, 22:655-662.
37. Fountzilas G., Dafni U., Dimopoulos M.A., Koutras A., Skarlos D., Papakostas P., et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: A Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 2009, 115:87-99.
38. Peacock N.W., Infante J.R., Yardley D.A., Burris H.A.I., Greco F.A., Farley C., et al. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC). J Clin Oncol 2008, 26:1032.
39. Baselga J., Carbonell X., Castaneda-Soto N.J., Clemens M., Green M., Harvey V., et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005, 23:2162-2171.
40. Bontenbal M., Seynaeve C., Stouthard J., Bos M., Braun H., Erdkamp F.L., et al. Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study). J Clin Oncol 2008, 26:1014.
41. Burris H., Yardley D., Jones S., Houston G., Broome C., Thompson D., et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004, 22:1621-1629.
42. Dati C., Antoniotti S., Taverna D., Perroteau I., De Bortoli M. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 1990, 5:1001-1006.
43. Kaufman B., Mackey J.R., Clemens M.R., Bapsy P.P., Vaid A., Wardley A., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 27:5529-5537.
44. Huober J., Fasching P., Paepke S., Kubista E., Barsoum M., Wallwiener D., et al. Letrozole in Combination with Trastuzumab Is Superior to Letrozole Monotherapy as First Line Treatment in Patients with Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer (MBC) - Results of the eLEcTRA Trial 2009, San Antonio Breast Cancer Symposium, San Antonio, Abstract 4094.
45. Johnston S., Pegram M., Press M., Pippen J., Pivot X., Gomez H., et al. Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial. San Antonio Breast Cancer Symposium 2008, Abstract 46.
46. Tolaney S.M., Krop I.E. Mechanisms of trastuzumab resistance in breast cancer. Anticancer Agents Med Chem 2009, 9:348-355.
47. Shirane M., Fujimoto-Ouchi K., Sekiguchi F. Preclinical study of continuous administration of trastuzumab as combination therapy after disease progression with trastuzumab monotherapy. Eur J Cancer Supp 2005, 2:411.
48. Fountzilas G., Razis E., Tsavdaridis D., Karina M., Labropoulos S., Christodoulou C., et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer 2003, 4:120-125.
49. Fabi A., Metro G., Ferretti G., Giannarelli D., Di Cosimo S., Papaldo P., et al. Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. Breast 2008, 17:499-505.
50. Stemmler H.J., Kahlert S., Siekiera W., Untch M., Heinrich B., Heinemann V. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie 2005, 28:582-586.
51. Adamo V., Franchina T., Adamo B., Ferraro G., Rossello R., Maugeri Sacca M., et al. Safety and efficacy of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experiences (GOIM study). Ann Oncol 2007, 18. vi11-vi15.
52. Bartsch R., Wenzel C., Hussian D., Pluschnig U., Sevelda U., Koestler W., et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer 2006, 6:63.
53. Cabarentes-Ocon F., Saez-Lara E., Burgos-Garcia L., Villar-Chamorro E., Casaus-Hazanas A., Luna S., et al. Retreatment with trastuzumab in HER2-positive metastatic breast cancer patients: a clinical study. Breast Cancer Res 2007, 9. S17.
54. Garcia-Saenz J.A., Martin M., Puente J., Lopez-Tarruella S., Casado A., Moreno F., et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer 2005, 6:325-329.
55. Jackisch C., Eustermann H., Schoenegg W., Soelling U., Stauch M., Goehler T., et al. Clinical use of trastuzumab (Herceptin) in metastatic breast cancer (MBC) in Germany from 2001 to 2006. San Antonio Breast Cancer Symposium 2007, Abstract 2134.
56. Menard S. Observational Demetra study: survival of metastatic breast carcinoma patients after treatment with trastuzumab. J Clin Oncol 2008, 26:1062.
57. Montemurro F., Redana S., Viale G., Sanna G., Donadio M., Valabrega G., et al. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. Clin Breast Cancer 2008, 8:436-442.
58. Gelmon K.A., Mackey J., Verma S., Gertler S.Z., Bangemann N., Klimo P., et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer discussion 2004, 5:59-62. 52-58.
59. Tripathy D., Slamon D.J., Cobleigh M., Arnold A., Saleh M., Mortimer J.E., et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004, 22:1063-1070.
60. Yeon C.H., Slamon D., Patel R., Cartmell A., Leyland-Jones B., Klein P., et al. Clinical benefit of trastuzumab (H) among patients with HER2-positive metastatic breast cancer (MBC) not achieving objective responses when treated with H plus chemotherapy (CT). J Clin Oncol 2004, 22:680.
61. Antoine E., Extra J., Vincent-Salomon A., Bergougnoux L., Capmana F., Namer M. Multiple lines of trastuzumab (Herceptin) may provide a survival benefit for women with HER2-positive metastatic breast cancer: data from the Hermine Cohort Study 2007, ASCO Breast Cancer Symposium, San Francisco, Abstract 230.
62. Rugo H., Kaufman P., Tan-Chiu E., Ulcickas Yood M., Paik S., Yardley D., et al. Survival of patients with HER2+ metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER. San Antonio Breast Cancer Symposium 2008, Abstract 3142.
63. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H., Sledge G., Koehler M., et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124-1130.
64. O'Shaughnessy J., Blackwell K.L., Burstein H., Storniolo A.M., Sledge G., Baselga J., et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 2008, 26:1015.
65. Matter-Walstra K.W., Dedes K.J., Schwenkglenks M., Brauchli P., Szucs T.D., Pestalozzi B.C. Trastuzumab beyond progression: a cost-utility analysis. Ann Oncol 2010, 21:2161-2168.
66. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009, 27:5278-5286.
67. Bartsch R., Rottenfusser A., Wenzel C., Dieckmann K., Pluschnig U., Altorjai G., et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 2007, 85:311-317.
68. Metro G., Sperduti I., Russillo M., Milella M., Cognetti F., Fabi A. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer. Oncologist 2007, 12:1467-1469. author reply 1469-1471.
69. Park I.H., Ro J., Lee K.S., Nam B.H., Kwon Y., Shin K.H. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol 2009, 20:56-62.
70. NCIC. Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer. identifier NCT00667251 [accessed September 2010]. http://www.clinicaltrials.gov.
71. Lazaridis G., Pentheroudakis G., Pavlidis N. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety. Crit Rev Oncol Hematol 2008, 66:31-41.
72. Madarnas Y., Trudeau M., Franek J.A., McCready D., Pritchard K.I., Messersmith H. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 2008, 34:539-557.
73. Buzdar A.U., Ibrahim N.K., Francis D., Booser D.J., Thomas E.S., Theriault R.L., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005, 23:3676-3685.
74. Chang H.R., Slamon D., Prati R., Glaspy J., Pegram M., Kass F.C., et al. A phase II study of neoadjuvant docetaxel/carboplatin with or without trastuzumab in locally advanced breast cancer: Response and cardiotoxicity. J Clin Oncol 2006, 24:10515.
75. Steger G.G., Greil R., Jakesz R., Lang A., Mlineritsch B., Melbinger-Zeinitzer E., et al. Final results of ABCG-24, a randomized phase III study comparing epirubicine, docetaxel, and capecitabine (EDC) and epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. San Antonio Breast Cancer Symposium 2009, Abstract 1081.
76. GlaxoSmithKline. Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study. identifier NCT00553358 [accessed September 2010]. http://www.clinicaltrials.gov.
77. Roche. A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Patients With HER2-Positive Breast Cancer. identifier NCT00976989 [accessed September 2010]. http://www.clinicaltrials.gov.
78. Roche. A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer. identifier NCT00545688 [accessed September 2010]. http://www.clinicaltrials.gov.
79. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
80. Lin N.U., Winer E.P. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007, 13:1648-1655.
81. Lin N.U., Carey L.A., Liu M.C., Younger J., Come S.E., Ewend M., et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008, 26:1993-1999.
82. Lin N.U., Dieras V., Paul D., Lossignol D., Christodoulou C., Stemmler H.J., et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009, 15:1452-1459.
83. ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study. identifier NCT 00490139 [accessed September 2010]. http://www.clinicaltrials.gov.
84. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009, 9:463-475.
85. Burstein H.J., Sun Y., Dirix L.Y., Jiang Z., Paridaens R., Tan A.R., et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010, 28:1301-1307.
86. Baselga J., Gelmon K.A., Verma S., Wardley A., Conte P., Miles D., et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010, 28:1138-1144.
87. Krop I.E., LoRusso P., Miller K.D., Modi S., Yardley D., Rodriguez G., et al. A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody-Drug Conjugate, in Patients Previously Treated with Lapatinib, Trastuzumab, and Chemotherapy. San Antonio Breast Cancer Symposium 2009, Abstract 5090.
88. Hurvitz S.A., Pegram M.D., Lin L.-S., Chan D.S., Allen H.J., Dichmann R.A., et al. Final Results of a Phase II Trial Evaluating Trastuzumab and Bevacizumab as First Line Treatment of HER2-Amplified Advanced Breast Cancer. San Antonio Breast Cancer Symposium 2009, Abstract 6094.
89. Pearson S.A., Ringland C.L., Ward R.L. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia-monitoring the effect of an expensive medicine access program. J Clin Oncol 2007, 25:3688-3693.